Phibro Animal Health (PAHC) Price Target Increased to $39.00 by Analysts at Credit Suisse Group

Phibro Animal Health (NASDAQ:PAHC) had its price objective increased by equities research analysts at Credit Suisse Group from $37.00 to $39.00 in a research note issued to investors on Tuesday, February 6th. The brokerage presently has a “neutral” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 9.40% from the stock’s current price.

A number of other research firms have also weighed in on PAHC. Zacks Investment Research lowered Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. BidaskClub downgraded Phibro Animal Health from a “sell” rating to a “strong sell” rating in a research report on Friday, January 26th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 price target on shares of Phibro Animal Health in a research report on Friday, November 10th. Finally, ValuEngine downgraded Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Phibro Animal Health has a consensus rating of “Hold” and an average price target of $38.20.

Shares of Phibro Animal Health (NASDAQ:PAHC) opened at $35.65 on Tuesday. The company has a current ratio of 3.12, a quick ratio of 1.75 and a debt-to-equity ratio of 1.82. The firm has a market capitalization of $1,408.69, a price-to-earnings ratio of 22.18, a price-to-earnings-growth ratio of 2.49 and a beta of 1.18. Phibro Animal Health has a twelve month low of $26.70 and a twelve month high of $40.25.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, February 5th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.06. The company had revenue of $205.90 million during the quarter, compared to analyst estimates of $194.90 million. Phibro Animal Health had a return on equity of 40.49% and a net margin of 7.90%. Phibro Animal Health’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.39 earnings per share. equities analysts forecast that Phibro Animal Health will post 1.69 EPS for the current year.

In related news, insider Dean J. Warras sold 10,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $35.62, for a total value of $356,200.00. Following the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $356,200. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Larry Lee Miller sold 14,182 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.49, for a total value of $503,319.18. Following the completion of the transaction, the chief operating officer now directly owns 8,582 shares in the company, valued at $304,575.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,754 shares of company stock worth $2,789,185. Insiders own 51.88% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Manhattan Co. acquired a new position in shares of Phibro Animal Health in the 4th quarter valued at $100,000. Dean Capital Investments Management LLC acquired a new position in shares of Phibro Animal Health in the 4th quarter valued at $200,000. Susquehanna International Group LLP acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at $219,000. Teacher Retirement System of Texas acquired a new position in shares of Phibro Animal Health in the 4th quarter valued at $224,000. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Phibro Animal Health in the 4th quarter valued at $253,000. 48.42% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://weekherald.com/2018/02/15/credit-suisse-group-increases-phibro-animal-health-pahc-price-target-to-39-00.html.

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply